NGFR and breast cancer: CD90 (Thy-1) is linked to tumorigenic potential in liver, lung, ovarian, and breast cancers, whereas CD271 (NGFR) is implicated in melanoma and head and neck cancers.157–161 Moreover, they contribute to cell migration, adhesion, and angiogenesis.